California Launches Affordable Insulin to Combat High Costs

California is set to make a significant change in the diabetes treatment landscape by launching its own brand of insulin, named CalRx, in January 2024. This long-acting insulin will be available for approximately $55, covering a month’s supply, a price point that aims to alleviate the financial burden on the state’s 3.5 million residents living with diabetes.

Emma Kleck, a 32-year-old resident of Santa Cruz, has relied on insulin since her Type 1 diabetes diagnosis at age 7. “I’m so reliant on this liquid,” she expressed, emphasizing that without insulin, she would struggle to function after just a few hours. The soaring costs of insulin in the United States have led many, including Kleck, to worry about affordability, with some patients resorting to rationing their supplies.

The introduction of CalRx is the result of Governor Gavin Newsom’s initiative, which began in 2020 with a plan to manufacture and sell insulin at lower prices. This announcement marks a pivotal moment, as it is the first instance of a U.S. state producing and selling its own insulin. The average price for insulin in 2019 was about $82 per month, highlighting the need for more affordable options.

In addition to CalRx, a new law signed by Newsom limits health insurance co-pays for insulin to $35 per month. This legislation, backed by state lawmakers such as Senators Scott Wiener and Aisha Wahab, is expected to take effect for many Californians as soon as January 2024, with others benefiting by January 2027.

Christine Fallabel, a policy executive for the American Diabetes Association, noted that these two initiatives work together to provide Californians with more affordable options than ever before. Nevertheless, the current offering of CalRx is limited to one type of insulin, glargine, which may not meet the needs of all Type 1 and Type 2 diabetes patients. Plans are in place to develop a fast-acting insulin as well.

The push for lower insulin prices has gained momentum in recent years, particularly since 2023, when pharmaceutical companies began voluntarily reducing costs in response to government interventions. Before these changes, a staggering 9% of individuals with diabetes were paying an average of $315 per month for their medication, according to KFF Health News.

“Insulin production is inexpensive, yet the costs to patients can vary widely based on insurance access and plan details,” noted Christine Christiansen, a mother of a Type 1 diabetes patient. Her son, Jack, diagnosed in 2017, currently benefits from his parents’ health insurance, but he remains anxious about his future coverage after turning 26.

A recent study by the Yale School of Medicine revealed that approximately 25% of the 8 million Americans using insulin are unable to afford it and are thus forced to ration their supplies. This practice can lead to severe health risks, including diabetic shock and other life-threatening complications.

Newsom’s administration asserts that CalRx will be more affordable because it is produced by Civica Rx, a nonprofit organization that manufactures generic medications without a profit motive. The state awarded Civica a $50 million contract, with the aim of ensuring that profits from CalRx sales will cover the costs of production moving forward.

The rising costs of insulin have captured national attention, prompting advocacy for reform. In 2022, President Joe Biden instituted a cap on insulin co-pays for Medicare recipients, and former President Donald Trump announced a similar deal for certain Novo Nordisk products.

The new CalRx insulin is designed to be interchangeable with Lantus, one of the most commonly prescribed insulins in the United States, produced by Sanofi, a French pharmaceutical company. Sanofi recently announced that it would offer Lantus at a reduced price of $35 per month through an expanded patient assistance program.

Evan Berland, a spokesperson for Sanofi, acknowledged that while some patients benefit from discount programs, many others struggle with the complexities involved in accessing these savings. In contrast, the CalRx insulin is expected to be more straightforward for patients to obtain, without the need for extensive paperwork.

Marilyn Tan, an endocrinologist at Stanford University, expressed enthusiasm for California’s initiative, although she cautioned that the costs associated with diabetes management extend beyond insulin alone. Patients often face additional expenses for insulin pumps, glucose monitoring devices, and other medications.

Looking ahead, California and Civica Rx are collaborating to introduce fast-acting insulin options in the future. This initiative aims to further support individuals managing diabetes and their healthcare needs.

With these developments, California’s approach to insulin affordability may serve as a model for other states grappling with the challenges of high medication costs, potentially leading to broader reforms in the healthcare system.